Homepage Hero – Triple NDA Filing Scientific Photo

Vertex Submits New Drug Application to the U.S. FDA for Triple Combination Regimen of VX-445 (Elexacaftor), Tezacaftor and Ivacaftor in Cystic Fibrosis

Vertex lab coat

FDA Approves SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for an Expanded Indication

Vertex scientist wearing goggles

Vertex Selects Triple Combination Regimen for Potential Global Regulatory Approvals in Cystic Fibrosis

Biotechnology to Create Transformative Medicines

At Vertex, we're relentless in our pursuit of medical research to create transformative medicines for people with serious and life-threatening diseases, like cystic fibrosis.

pipeline and medicine

PIPELINE & MEDICINES
Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.
 

working here

WORKING HERE
At Vertex, we have some of the industry's best and brightest people helping us achieve our mission of discovering transformative medicines to help people with serious diseases, like cystic fibrosis. 

news

NEWS
Vertex Submits New Drug Application to the U.S. FDA for Triple Combination Regimen of VX-445 (Elexacaftor), Tezacaftor and Ivacaftor in Cystic Fibrosis

Follow Us for Updates